Reskuin en es it fr

Reskuin Brand names, Reskuin Analogs

Reskuin Brand Names Mixture

  • No information avaliable

Reskuin Chemical_Formula

C36H42F2N6O9

Reskuin RX_link

http://www.rxlist.com/cgi/generic2/quixin.htm

Reskuin fda sheet

Reskuin FDA

Reskuin msds (material safety sheet)

Reskuin Synthesis Reference

Mitscher, Lester A. et al.; J.Med.Chem.; 30; 12; 2283-2286(1987)

Reskuin Molecular Weight

740.751 g/mol

Reskuin Melting Point

No information avaliable

Reskuin H2O Solubility

Insoluble

Reskuin State

Solid

Reskuin LogP

1.268

Reskuin Dosage Forms

Tablet; Liquid; Solution

Reskuin Indication

For the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Corynebacterium species, Staphylococus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Streptococcus (Groups C/F/G), Viridans group streptococci, Acinetobacter lwoffii, Haemophilus influenzae, Serratia marcescens.

Reskuin Pharmacology

Levofloxacin, a fluoroquinolone antiinfective, is the optically active L-isomer of ofloxacin. Levofloxacin is used to treat bacterial conjunctivitis, sinusitis, chronic bronchitis, community-acquired pneumonia and pneumonia caused by penicillin-resistant strains of Streptococcus pneumoniae, skin and skin structure infections, complicated urinary tract infections and acute pyelonephritis.

Reskuin Absorption

Absorption of ofloxacin after single or multiple doses of 200 to 400 mg is predictable, and the amount of drug absorbed increases proportionately with the dose.

Reskuin side effects and Toxicity

Side effects include disorientation, dizziness, drowsiness, hot and cold flashes, nausea, slurring of speech, swelling and numbness in the face

Reskuin Patient Information

PATIENT INFORMATION

While taking ofloxacin patient should be advised to:

— to drink fluids liberally;

— that mineral supplements, vitamins with iron or minerals, calcium- , aluminum-, or magnesium-based antacids, sucralfate or Videx®, (Didanosine), chewable/buffered tablets or the pediatric powder for oral solution should not be taken within the two-hour period before or within the two-hour period after taking ofloxacin;

— that ofloxacin can be taken without regard to meals;

— that ofloxacin may cause neurologic adverse effects (e. g. , dizziness, lightheadedness) and that patients should know how they react to ofloxacin before they operate an automobile or machinery or engage in activities requiring mental alertness and coordination;

— to discontinue treatment and inform their physician if they experience pain, inflammation, or rupture of a tendon, and to rest and refrain from exercise until the diagnosis of tendinitis or tendon rupture has been confidently excluded;

— that ofloxacin may be associated with hypersensitivity reactions, even following the first dose, to discontinue the drug at the first sign of a skin rash, hives or other skin reactions, a rapid heartbeat, difficulty in swallowing or breathing, any swelling suggesting angioedema (e. g. , swelling of the lips, tongue, face; tightness of the throat, hoarseness), or any other symptom of an allergic reaction

— to avoid excessive sunlight or artificial ultraviolet light while receiving ofloxacin and to discontinue therapy if phototoxicity (e. g. , skin eruption) occurs;

— that if they are diabetic and are being treated with insulin or an oral hypoglycemic drug, to discontinue ofloxacin immediately if a hypoglycemic reaction occurs and consult a physician;

— that convulsions have been reported in patients taking quinolones, including ofloxacin, and to notify their physician before taking this drug if there is a history of this condition.

Reskuin Organisms Affected

Enteric bacteria and other eubacteria